Format

Send to

Choose Destination
Clin Cancer Res. 2017 May 15;23(10):2451-2459. doi: 10.1158/1078-0432.CCR-16-1780. Epub 2016 Nov 10.

Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial.

Author information

1
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (SKCCC), Baltimore, Maryland.
2
Brigham and Women's Hospital/Dana-Farber Cancer Center, Boston, Massachusetts.
3
University of Washington and Seattle Cancer Care Alliance, Seattle, Washington.
4
The Urology Center of Colorado, Denver, Colorado.
5
Dana-Farber Cancer Institute, Boston, Massachusetts.
6
Carolina Urologic Research Center, Myrtle Beach, South Carolina.
7
US Oncology Research Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada.
8
Virginia Mason Medical Center, Seattle, Washington.
9
Moores UCSD Cancer Center, La Jolla, California.
10
Dendreon Pharmaceuticals Inc., Seattle, Washington.
11
Johns Hopkins SKCCC, the Brady Urological Institute and the Bloomberg Kimmel Institute, Baltimore, Maryland. cgd2139@cumc.columbia.edu.

Abstract

Purpose: STAND, a randomized, phase II, open-label trial (NCT01431391), assessed sequencing of sipuleucel-T (an autologous cellular immunotherapy) with androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC) patients at high risk for metastasis.Experimental Design: Men with BRPC following prostatectomy and/or radiotherapy, a PSA doubling time ≤12 months, and no metastasis were enrolled. Patients were randomized (34/arm) to sipuleucel-T followed by ADT (started 2 weeks after sipuleucel-T completion), or ADT followed by sipuleucel-T (started 12 weeks after ADT initiation); ADT continued for 12 months in both arms. The primary endpoint was PA2024-specific T-cell response [enzyme-linked immunospot (ELISPOT)] over time.Results: PA2024-specific ELISPOT responses over time were similar between groups, except at week 6, where responses were higher with sipuleucel-T→ADT versus ADT→sipuleucel-T (P = 0.013). PA2024-specific T-cell proliferation responses, averaged across time points, were approximately 2-fold higher with sipuleucel-T→ADT versus ADT→sipuleucel-T (P = 0.001). PA2024-specific cellular and humoral responses and prostatic acid phosphatase-specific humoral responses increased significantly versus baseline (P < 0.001) and were maintained for 24 months (both arms). Median time-to-PSA recurrence was similar between arms (21.8 vs. 22.6 months, P = 0.357). Development of a PA2024-specific humoral response correlated with prolonged time-to-PSA progression (HR, 0.22; 95% CI, 0.08-0.67; P = 0.007). Sipuleucel-T with ADT was generally well tolerated.Conclusions: Sipuleucel-T→ADT appears to induce greater antitumor immune responses than the reverse sequence. These results warrant further investigation to determine whether this sequence leads to improved clinical outcomes, as well as the independent contribution of ADT alone in terms of immune activation. Clin Cancer Res; 23(10); 2451-9. ©2016 AACR.

PMID:
27836866
DOI:
10.1158/1078-0432.CCR-16-1780
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center